Fate Therapeutics, Inc. – NASDAQ:FATE

Add to watchlist

$1.14

-0.47

-29.2%

Market closed

Open in about 8 hours

-55.40%

month

-55.40%

quarter

-56.01%

year

Market Cap	179.83M
Enterprise value	596.33M

P/E	-1.82
EV/Sales	6.19
EV/EBITDA	-2.27
Price/Sales	5.69
Price/Book	1.13
PEG ratio	0.06
EPS	-1.92

Revenue	6.47M
EBITDA	-198.81M
Income	-190.05M
Revenue Q/Q	-96.73%
Revenue Y/Y	-95.26%

Profit margin	-292.55%
Oper. margin	-320.23%
Gross margin	0%
EBIT margin	-320.23%
EBITDA margin	-3069.08%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Fate Therapeutics Stock Forecast

M Q Y

Last Year

Potential upside: 338.67%

Analysts Price target
Financials & Ratios estimates

Fate Therapeutics, Inc. (NASDAQ:FATE): Profit margin
Jun 2023	933K	-52.75M	-5654.34%
Sep 2023	1.94M	-45.17M	-2323.56%
Dec 2023	1.67M	-44.12M	-2632.58%
Mar 2024	1.92M	-48.00M	-2493.71%

Fate Therapeutics, Inc. (NASDAQ:FATE): Debt to assets
Jun 2023	584757000	147.00M	25.14%
Sep 2023	543788000	141.01M	25.93%
Dec 2023	506217000	137.8M	27.22%
Mar 2024	569892000	143.77M	25.23%

Fate Therapeutics, Inc. (NASDAQ:FATE): Cash Flow
Jun 2023	-28.49M	33.16M	58K
Sep 2023	-38.27M	24.80M	0
Dec 2023	-36.63M	45.35M	-180K
Mar 2024	-33.35M	17.31M	95.48M

Fate Therapeutics alternative data

Fate Therapeutics, Inc. (NASDAQ:FATE): Employee count
Aug 2023	551
Sep 2023	551
Oct 2023	551
Nov 2023	551
Dec 2023	551
Jan 2024	551
Feb 2024	551
Mar 2024	181
Apr 2024	181
May 2024	181
Jun 2024	181
Jul 2024	181

Fate Therapeutics
Hedge Funds Holdings Q1 2022

100.00% 0.00%

of FATE is owned by hedge funds

235 -5

hedge funds hold FATE stock

100.51M +3.74M

shares is hold by hedge funds

FATE hedge funds holdings changes

Fate Therapeutics
Insider Trading

Fate Therapeutics, Inc. (NASDAQ:FATE): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	50595
Mar 2024	0	2447
Aug 2024	0	633
Dec 2024	397964	341633

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	20 Dec 2024	REDMILE GROUP, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	397,964	$1.68	$668,580
Sale	20 Dec 2024	REDMILE GROUP, LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	341,633	$1.68	$573,943
Sale	6 Aug 2024	XU YUAN director director	Common Stock	633	$4.23	$2,678
Sale	4 Mar 2024	DULAC EDWARD J III officer: Chief Fi..	Common Stock	2,447	$7.77	$19,013
Sale	29 Jan 2024	DULAC EDWARD J III officer: Chief Fi..	Common Stock	1,849	$5	$9,245
Sale	9 Jan 2024	DULAC EDWARD J III officer: Chief Fi..	Common Stock	7,028	$4.37	$30,712
Sale	9 Jan 2024	TAHL CINDY officer: General ..	Common Stock	10,874	$4.37	$47,519
Sale	9 Jan 2024	VALAMEHR BAHRAM officer: Chief R&..	Common Stock	11,271	$4.38	$49,367
Sale	9 Jan 2024	WOLCHKO J SCOTT director, officer..	Common Stock	14,391	$4.37	$62,889
Sale	2 Jan 2024	DULAC EDWARD J III officer: Chief Fi..	Common Stock	5,182	$3.66	$18,966

FATE insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF Filling date: 17 Jul 2020 Issue date: 1 Sep 2022	17 Jul 2020	1 Sep 2022
Grant	Grant Utility: Compositions and methods for immune cell modulation in adoptive immunotherapies Filling date: 20 Jan 2017 Issue date: 16 Aug 2022	20 Jan 2017	16 Aug 2022
Application	Application REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS Filling date: 19 Jan 2022 Issue date: 21 Jul 2022	19 Jan 2022	21 Jul 2022
Grant	Grant Utility: Enhanced immune effector cells and use thereof Filling date: 19 Feb 2021 Issue date: 21 Jun 2022	19 Feb 2021	21 Jun 2022
Application	Application CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS Filling date: 8 Apr 2020 Issue date: 16 Jun 2022	8 Apr 2020	16 Jun 2022
Grant	Grant Utility: Genomic engineering of pluripotent cells Filling date: 17 Oct 2019 Issue date: 7 Jun 2022	17 Oct 2019	7 Jun 2022
Application	Application IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS Filling date: 25 Nov 2019 Issue date: 28 Apr 2022	25 Nov 2019	28 Apr 2022
Application	Application ENHANCED STEM CELL COMPOSITION Filling date: 4 Jun 2021 Issue date: 21 Apr 2022	4 Jun 2021	21 Apr 2022
Grant	Grant Utility: Reprogramming methods and cell culture platforms Filling date: 4 Mar 2015 Issue date: 8 Mar 2022	4 Mar 2015	8 Mar 2022
Application	Application METHODS OF TREATING ISCHEMIA Filling date: 12 Apr 2021 Issue date: 24 Feb 2022	12 Apr 2021	24 Feb 2022

Fate Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 26 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

FATE earnings call transcripts

Fate Therapeutics
Executives

Insider	Age	Compensation
Mr. J. Scott Wolchko (1970) Founder, Chief Executive Officer, Pres & Director	55	$926,250
Ms. Cindy R. Tahl (1973) Gen. Counsel & Corporation Sec.	52	$585,000
Dr. Bahram Valamehr Ph.D. (1977) Chief R&D Officer	48	$585,000
Mr. Edward J. Dulac III (1975) Chief Financial Officer & Principal Accounting Officer	50	$476,250

Fate Therapeutics
Latest News

Thursday, 12 December 2024
12:36	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?	zacks.com
Monday, 9 December 2024
16:01	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus	globenewswire.com
Tuesday, 3 December 2024
16:01	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Friday, 29 November 2024
13:05	Fate Therapeutics Announces Leadership Transition	globenewswire.com
Tuesday, 26 November 2024
16:01	Fate Therapeutics to Present at Upcoming December Investor Conferences	globenewswire.com
Wednesday, 20 November 2024
16:34	Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options	seekingalpha.com
Tuesday, 19 November 2024
14:55	FATE Presents Encourgaing Data From Lupus Study, Stock Gains	zacks.com
Monday, 18 November 2024
08:05	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence	globenewswire.com
Wednesday, 13 November 2024
12:21	FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus	zacks.com
Tuesday, 12 November 2024
18:21	Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:01	Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates	globenewswire.com
Saturday, 9 November 2024
13:30	Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting	globenewswire.com
Friday, 8 November 2024
16:01	Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting	globenewswire.com
Monday, 4 November 2024
16:01	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 2 October 2024
16:01	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 12 September 2024
16:01	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference	globenewswire.com
12:30	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?	zacks.com
Friday, 16 August 2024
13:00	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy	zacks.com
Wednesday, 14 August 2024
11:11	FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow	zacks.com
Tuesday, 13 August 2024
18:25	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:05	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates	globenewswire.com
Friday, 2 August 2024
16:01	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Sunday, 21 July 2024
05:37	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?	fool.com
Tuesday, 2 July 2024
16:01	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 13 June 2024
08:00	FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm	prnewswire.com
Tuesday, 4 June 2024
16:01	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 29 May 2024
16:01	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference	globenewswire.com
Monday, 20 May 2024
05:04	Russell Investments Group Ltd. Acquires 59,267 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)	https://www.defenseworld.net
01:38	Fate Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.40) Per Share (NASDAQ:FATE)	https://www.defenseworld.net
Saturday, 11 May 2024
18:12	Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript	Seeking Alpha

Ideas & Opinions

Seeking Alpha 8 May 2025

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
Seeking Alpha 29 Apr 2024

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
Seeking Alpha 29 Apr 2024

Fate Therapeutics: Looking For A Potential Turnaround In 2024
Seeking Alpha 12 Nov 2023

Fate Therapeutics: Getting There, But Perpetually
Seeking Alpha 23 May 2023

Fate Therapeutics: The Future Remains Cloudy
Seeking Alpha 26 Mar 2023

Nkarta: Going Down Despite Solid Data Due To Fate's Debacle
Seeking Alpha 6 Jan 2023

ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances
Seeking Alpha 5 Jan 2023

Fate Therapeutics: iPSC Pioneer A Buy For Long-Term Investors
Seeking Alpha 15 Nov 2022

Fate Therapeutics: Returning To The Ticker That Changed The Way I Invest
Seeking Alpha 10 Nov 2022

Nkarta: Under The Radar Company With Brilliant Results

Frequently Asked Questions (FAQ)

What's the price of Fate Therapeutics stock today?

One share of Fate Therapeutics stock can currently be purchased for approximately $1.14.
When is Fate Therapeutics's next earnings date?

Unfortunately, Fate Therapeutics's (FATE) next earnings date is currently unknown.
Does Fate Therapeutics pay dividends?

No, Fate Therapeutics does not pay dividends.
How much money does Fate Therapeutics make?

Fate Therapeutics has a market capitalization of 179.83M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 34.03% to 63.53M US dollars.
What is Fate Therapeutics's stock symbol?

Fate Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FATE".
What is Fate Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Fate Therapeutics?

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Fate Therapeutics's key executives?
Fate Therapeutics's management team includes the following people:
- Mr. J. Scott Wolchko Founder, Chief Executive Officer, Pres & Director(age: 55, pay: $926,250)
- Ms. Cindy R. Tahl Gen. Counsel & Corporation Sec.(age: 52, pay: $585,000)
- Dr. Bahram Valamehr Ph.D. Chief R&D Officer(age: 48, pay: $585,000)
- Mr. Edward J. Dulac III Chief Financial Officer & Principal Accounting Officer(age: 50, pay: $476,250)
Is Fate Therapeutics founder-led company?

Yes, Fate Therapeutics is a company led by its founder Mr. J. Scott Wolchko.
How many employees does Fate Therapeutics have?

As Jul 2024, Fate Therapeutics employs 181 workers.
When Fate Therapeutics went public?

Fate Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 1 Oct 2013.
What is Fate Therapeutics's official website?

The official website for Fate Therapeutics is fatetherapeutics.com.
Where are Fate Therapeutics's headquarters?

Fate Therapeutics is headquartered at 12278 Scripps Summit Drive, San Diego, CA.
How can i contact Fate Therapeutics?

Fate Therapeutics's mailing address is 12278 Scripps Summit Drive, San Diego, CA and company can be reached via phone at 858 875 1800.
What is Fate Therapeutics stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Fate Therapeutics in the last 12 months, the avarage price target is $5. The average price target represents a 338.67% change from the last price of $1.14.

Fate Therapeutics, Inc.

fatetherapeutics.com

Exchange:

NASDAQ

Full time employees:

181

Industry:

Biotechnology

Sector:

Healthcare

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

858 875 1800

12278 Scripps Summit Drive
San Diego, CA 92131

CIK: 0001434316
ISIN: US31189P1021
CUSIP: 31189P102